Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA 19107, United States.
Pharmacol Res. 2012 Jan;65(1):48-55. doi: 10.1016/j.phrs.2011.09.001. Epub 2011 Sep 10.
Tumor necrosis factor alpha (TNF-α) plays a major role in the pathogenesis of many inflammatory diseases. Neutralizing TNF-α by antibodies or antisense oligodeoxynucleotides, alleviate disease symptoms. In this study, we introduce the new generation of gene-silencing molecules, namely the small interfering RNAs (siRNAs) to reduce TNF-α. Although siRNAs of 19-21bp are commonly used, it is reported that longer siRNAs have much higher efficacies. Here, we report the identification of a 27-mer Dicer-substrate siRNA (DsiRNA) against TNF-α mRNA. Primary cells of rat Kupffer cells were transfected with five 27-mer siRNA constructs (si27-1, si27-2 si27-3, si27-4 and si27-5) for 24h, following which, TNF-α secretion was induced by exposure to LPS (0.1μg/ml) for 2h. TNF-α released to the medium was measured by ELISA. Of the five si27 constructs, si27-3 had the highest inhibitory effect on TNF-α secretion. At 10nM, si27-3 inhibited TNF-α secretion by 80% compared to a 60% inhibition by a 21-mer (SSL3). Following encapsulation in anionic liposomes, si27-3 at 100μg/kg body weight, on two successive days by intravenous administration, inhibited the secretion of TNF-α by 50%. These data demonstrate the identification of a highly efficacious siRNA formulation, which can be used in the treatment of TNF-α mediated diseases.
肿瘤坏死因子-α(TNF-α)在许多炎症性疾病的发病机制中起主要作用。通过抗体或反义寡脱氧核苷酸中和 TNF-α,可以缓解疾病症状。在这项研究中,我们引入了新一代基因沉默分子,即小干扰 RNA(siRNA)来降低 TNF-α。虽然通常使用 19-21bp 的 siRNA,但据报道,更长的 siRNA 具有更高的功效。在这里,我们报告了一种针对 TNF-α mRNA 的 27 个碱基的 Dicer 底物 siRNA(DsiRNA)的鉴定。用五种 27 个碱基的 siRNA 构建体(si27-1、si27-2、si27-3、si27-4 和 si27-5)转染大鼠枯否细胞原代细胞 24 小时,然后用 LPS(0.1μg/ml)孵育 2 小时诱导 TNF-α 分泌。通过 ELISA 测量释放到培养基中的 TNF-α。在这五个 si27 构建体中,si27-3 对 TNF-α 分泌的抑制作用最高。在 10nM 时,与 21 个碱基的 SSL3 相比,si27-3 抑制 TNF-α 分泌 80%。在阴离子脂质体包封后,si27-3 以 100μg/kg 体重,连续两天静脉注射,可抑制 TNF-α 的分泌 50%。这些数据表明鉴定出一种高效的 siRNA 制剂,可用于治疗 TNF-α 介导的疾病。